For ACRE open hearing on the criticisms of T25 GM maize risk assessment
The hearing will take place from 10.00am to 2.00pm on Wednesday, 20
February, in Room 7A, B and C, Ashdown House, Department for Environment, Food and Rural Affairs, 123 Victoria Street, London SW1E 6DE.
Dr. Mae-Wan Ho, Institute of Science in Society, UK
I am speaking against the market approval of T25 because there is no evidence that it is a genetically stable, uniform line, the single most important criterion for approval. For unless it is genetically stable, you might as well forget about environmental or health risk assessment. And genetic instability is also a serious safety issue. The public hearing on T25 was suspended over a year ago when it was found not to have passed the required EC test for Distinctiveness, Uniformity and Stability (the DUS test), as I pointed out when giving evidence to the hearing [1].
The new EC Directive on deliberate release requires strict molecular evidence of genetic stability, which is also necessary for establishing the identity of the transgenic line and to ensure traceability. The best-kept secret of GM crops is that they are not stable.
There is a large literature on gene silencing, in which the transgenes remain in the genome, but are not expressed. More serious, from the safety point of view, is structural instability, the tendency for the transgenic DNA to come loose, to rearrange or become lost in part or in whole in successive generations [2,3]. This could change the transgenic line in unpredictable ways in terms of health and environmental risks. And it will increase the chance of transgenic DNA being taken up by unrelated species to make new combinations with their genetic material. Thats referred to as horizontal gene transfer and recombination. Transgenic DNA can spread to every species that interact with the transgenic plant, in the soil, in the air, in the mouth and gut and the respiratory tracts of animals including human beings.
New viruses and bacteria that cause diseases could be generated, and antibiotic resistance marker genes could spread to the pathogens. Transgenic DNA may also get into human cells and insert into the human genome; and a large body of evidence from so-called gene therapy experiments have amply demonstrated this does occur [4]. The constructs used in gene therapy are very similar to those used in transgenic plants, and one main side-effect of transgenic DNA inserting into human genome during gene therapy is cancer.
Despite that, our regulators have not required biotech companies to provide molecular evidence of stability. ACREs latest guidelines for industry put out for public consultation asks industry to provide molecular evidence of genetic stability over one generation only [5], which is derisory. We need data for at least five successive generations [6]. No such data have come forward from the companies. On the contrary, companies have been allowed to hide under commercial confidentiality.
I am putting to you twelve reasons why trangenic DNA is different from natural DNA, and is more likely to spread by horizontal gene transfer and recombination, both by design and otherwise. I hope you will refute these point by point.
(The details are in two ISIS reprint collections on transgenic instability and horizontal gene transfer that I am presenting to ACRE, for free.)
In summary, there is no reason to believe T25 is stable. Furthermore, it has especially hazardous sequences, including the CaMV 35S promoter and an ampicillin resistance gene that, though inactive, can easily be transferred into integrons that will provide it with a promoter to make it functional [1]. T25 has uncharacterised sequences that might be involved in causing diseases. Finally, it has an origin of replication, which enables the transgenic DNA to be replicated as a plasmid if transferred into bacteria, thereby greatly increasing horizontal gene transfer on to other species. The origin of replication is also a recombination hotspot, and there have been strong recommendations from a recent joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology that transgenic lines containing this sequence should not be approved on safety grounds [24].
Article first published 13/02/02